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Reply
SIR, The severe infections observed by Estrach et al. in patients
with underlying chest disease highlight the necessity to screen
patients carefully before initiating anti-tumour necrosis factor
(TNF-) therapy. A formalized, structured screening process
encompassing a history of infections, possible exposure to
mycobacteria, tuberculin testing and a chest X-ray examination
can help to identify potential pitfalls. A low threshold to adding
culture and polymerase chain reaction testing of urine and sputum
for mycobacterial species, high-resolution computed tomography
scanning and bronchoscopy to clarify uncertainties is warranted.
As Estrach et al. point out, the costs involved are negligible
compared with those of the medication itself and of hospitalization
for severe infections. Should predisposing conditions be identiﬁed,
a multidisciplinary approach to decide on the appropriate mea-
sures is necessary, as is ensuring rapid intervention should the
suspicion of infection arise.
In this context, the concealment of symptoms by patients
described by Dr Kiely must be taken seriously. Symptom
concealment may result from concern that the responsible physi-
cian will discontinue anti-TNF- therapy indeﬁnitely, because
patients are reluctant to go through yet another series of medical
tests and therapies, or from the masking of symptoms by anti-
TNF- therapy itself. This makes it even more urgent to clarify
slight alterations in well-being. We attempt to reassure patients at
each visit that prompt diagnosis and, if necessary, speciﬁc therapy
are an integral part of maintaining the beneﬁts of biological agents
while minimizing the morbidity and costs due to serious undesired
effects.
To achieve this aim, it is essential that all physicians, including
those in practice, be well informed of possible undesired effects.
When infection is suspected, rapid and thorough investigation to
identify its origin, localization and responsible agent is important
to guide targeted therapy. To raise awareness of such undesired
effects in patients, their relatives and acquaintances and physi-
cians, we can only support the idea of a patient alert card. In fact,
at a recent information gathering for patients with rheumatoid
arthritis and their relatives, the suggestion of alert cards was
warmly received. In Switzerland two of the three suppliers of anti-
TNF- agents provide such cards. Ideally, these would be
standardized, with a telephone hotline and links to information
on the internet.
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